Indivior ends PAM drug collab with Addex ahead of Supernus merger
Why now
Thesis: Partnership termination precedes Supernus merger
Catalyst to watch: Merger completion or pipeline updates
Main risk: Lost collaboration weakens R&D outlook
Why it matters
Ending a drug collaboration ahead of a merger removes a pipeline asset and signals integration friction.
Related assets & topics
HealthcareSources
- googlenews · news.google.com · 2026-09-25 09:23 UTC
- googlenews · news.google.com · 2026-09-25 09:23 UTC